Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Comparative risks

Typical analysis for the neutralization wet process product is given in Table 5. Sodium cyanide is packed in mild steel or fiber dmms and in 1.4 t Flo-bins. Dry sodium cyanide is also shipped in wet-flo tank cars and tmcks of up to 32 t net. At destination, water is circulated through the wet-flo car or trailer to dissolve the dry sodium cyanide at deUvery. This type of shipment reduces freight costs and reduces environmental risks compared with 30% aqueous solution shipment. Safety regulations are imposed by the various shipping lines and by the countries in which cyanide is transported. [Pg.383]

Chemical Industry - has risks comparable to or possibly greater then those of the nuclear power industry, but no risk studies of chemical plants in the U.S. have been published. Great Britain, on the other hand, has been active in this area, e.g., the Canvey Island Study (Section 11.4.1 and Green, 1982). [Pg.17]

The European Stroke Prevention Study 2 (ESPS-2) trial examined four treatment arms—extended-release dipyridamole (ER-DP) 200 mg twice daily alone, aspirin 25 mg twice daily alone, ER-DP 200 mg twice daily + aspirin 25 mg twice daily, or placebo. In comparison with placebo the overall reduction in stroke risk was 16% with ER-DP alone and 18% with aspirin alone. The combination of ER-DP and aspirin led to a 37% reduction in stroke risk compared to placebo. Compared with aspirin alone, the combination of ER-DP with aspirin reduced the risk of stroke by 23%. [Pg.148]

The WHI trial showed an overall increase in the risk of coronary heart disease in healthy postmenopausal women aged 50 to 79 years taking estrogen-progestogen therapy compared with those taking placebo. The increased risk of coronary heart disease was most apparent at 1 year. The estrogen-alone arm of the WHI showed no effect (either increase or decrease) in the risk of coronary heart disease. Recent analysis showed that women who started hormone therapy closer to the time of menopause tended to have decreased coronary heart disease risk compared to the... [Pg.362]

Avoiding one risk may create a new risk net risk is always a consideration. Thus, the risk assessment analyses trade-off in risk, compares risk levels, and evaluates cost-effectiveness of risk reduction alternatives. [Pg.78]

Case-control study Ever-users of oral contraceptives had 1.1 risk compared with never-users higher doses produce a slightly higher risk duration of use irrelevant family history higher risk use after age 40 risk increased by 50% (139)... [Pg.184]

A number of antidepressant drugs, particularly SSRIs, can increase plasma prolactin concentrations, although galactorrhea is uncommon. In a prescription event monitoring survey of about 65 000 patients, compared with SSRIs, moclobemide was associated with a relative risk of galactorrhea of 6.7 (95% Cl = 2.7, 15) (727). However, this was substantially less than the risk associated with the dopamine receptor antagonist risperidone (relative risk compared with SSRIs 32 95% Cl = 14, 70). [Pg.623]

Most people believe AAS users take them because they want to improve their physical appearance. In fact, teens surveyed named this for a primary reason, as opposed to improving sport performance. One study found AAS users tend to have more narcissistic personalities traits, defined as excessive admiration of oneself, and have less empathy. It is unclear whether these traits contribute to starting AASs or result from the use of steroids. Adolescents are less likely than they were a decade ago to disapprove of short-term steroid use or to view it as a great risk. In the 2001 Monitoring the Future survey, 60% saw it as a great risk compared to 70% in... [Pg.460]

Another method of expressing risk is an index of relative risk. This measure is calculated for a group of workers as the ratio of the rate for that group to the rate for all workers.3 The index of relative risk compares the fatality risk of a group of workers with all workers. For example, the relative risk for truck drivers in Table 1—3 is 5.3, which means that they are roughly five times as likely to have a fatal work injury as the average worker. [Pg.12]

Relative Risks Compared to the Chemical Industry Jobs... [Pg.14]

Tools should be developed to support the identification of mixture exposure situations that may cause unexpectedly high risks compared to the standard null models of CA and RA, for example, based on an analysis of food consumption and behavioral patterns, and the occurrence of common mixture combinations that cause synergistic effects. [Pg.212]

The safety of ultrafine particles remains to be clearly elucidated and requires the collaborative input of toxicologists (animal, cellular, molecular), epidemiologists, clinicians (pulmonary, cardiovascular, neurological), and atmospheric scientists. There are several published studies to indicate that ultrafine particles pose a higher toxicity risk compared with their larger counterparts [258-261], Figure 1 outlines the potential effects of ultrafine particles on respiratory mucosa, the cardiovascular system, and central and peripheral nervous systems, upon inhalation. [Pg.1309]

Because products assessed in a LCA are often characterised quantitatively in terms of function, comparisons can be made of product lifetime or durability and efficiency. For example, one paint may have greater covering power than the other or one paint may be more durable. In some cases, product performance can be an important variable for determining chemical exposure during the various stages of the product s lifecycle, thereby having implications to risks. Comparative risk assessments between two or more products or processes may therefore also be done on a functional unit basis. [Pg.377]

These studies both reveal a high vascular risk compared with the normal population, with this risk continuing up to 10 or 15 years and probably beyond following TIA. They, therefore, support the ongoing use of secondary preventive medication. [Pg.215]


See other pages where Comparative risks is mentioned: [Pg.530]    [Pg.334]    [Pg.137]    [Pg.333]    [Pg.194]    [Pg.27]    [Pg.17]    [Pg.13]    [Pg.306]    [Pg.314]    [Pg.157]    [Pg.624]    [Pg.84]    [Pg.186]    [Pg.188]    [Pg.218]    [Pg.623]    [Pg.122]    [Pg.201]    [Pg.98]    [Pg.529]    [Pg.166]    [Pg.148]    [Pg.49]    [Pg.127]    [Pg.143]    [Pg.199]    [Pg.79]    [Pg.183]   
See also in sourсe #XX -- [ Pg.305 , Pg.307 ]




SEARCH



Compare Risks

© 2024 chempedia.info